Analyst Ratings For NASDAQ:TGTX – TG Therapeutics (NASDAQ:TGTX)
Today, Raymond James reiterated its Buy rating on NASDAQ:TGTX – TG Therapeutics (NASDAQ:TGTX).
Some recent analyst ratings include
- 4/19/2018-Raymond James Reiterated Rating of Buy.
- 3/9/2018-B. Riley Reiterated Rating of Buy .
- 1/16/2018-HC Wainwright Reiterated Rating of Buy.
- 10/3/2017-SunTrust Banks Reiterated Rating of Buy.
- 6/17/2017-FBR & Co Reiterated Rating of Buy.
- 6/5/2017-Jefferies Group Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:TGTX – TG Therapeutics (NASDAQ:TGTX)
NASDAQ:TGTX – TG Therapeutics (NASDAQ:TGTX) has insider ownership of 16.70% and institutional ownership of 47.33%.
- On 1/2/2018 Sean A Power, CFO, sold 32,006 with an average share price of $8.50 per share and the total transaction amounting to $272,051.00.
- On 6/19/2017 Sean A Power, CFO, sold 59,976 with an average share price of $11.09 per share and the total transaction amounting to $665,133.84.
- On 4/11/2017 William James Kennedy, Director, sold 8,548 with an average share price of $10.27 per share and the total transaction amounting to $87,787.96.
- On 4/4/2017 Laurence N. Charney, Director, sold 7,000 with an average share price of $11.17 per share and the total transaction amounting to $78,190.00.
- On 1/4/2017 Sean A. Power, CFO, sold 8,816 with an average share price of $4.55 per share and the total transaction amounting to $40,112.80.
- On 4/18/2016 Sean A Power, CFO, sold 10,000 with an average share price of $10.12 per share and the total transaction amounting to $101,200.00.
- On 1/5/2016 Sean A Power, CFO, sold 22,790 with an average share price of $11.21 per share and the total transaction amounting to $255,475.90.
Recent Trading Activity for NASDAQ:TGTX – TG Therapeutics (NASDAQ:TGTX)
Shares of NASDAQ:TGTX – TG Therapeutics closed the previous trading session at 14.75 up +0.55 3.87% with 14.199999809265137 shares trading hands.